Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers

Medicine and Dentistry

• Systemic Scleroderma 100%
• Pulmonary Hypertension 71%
• Endothelin 1 42%
• Therapeutic Procedure 42%
• Diseases 28%
• Development 28%
• Blood Vessel Injury 28%
• Bosentan 28%
• Patient 28%
• Inpatient 28%
• Morbidity 14%
• Complication 14%
• Combination Therapy 14%
• Pathophysiology 14%
• Autoimmune Disease 14%
• Evaluation Study 14%
• Receptor Blocking Agent 14%
• Pulmonary Fibrosis 14%
• Mortality 14%
• Finger Ulcer 14%
• Vascular Fibrosis 14%
• Recognition 14%
• Organ 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Systemic Sclerosis 100%
• Pulmonary Hypertension 71%
• Endothelin 1 42%
• Diseases 28%
• Blood Vessel Injury 28%
• Bosentan 28%
• Complication 14%
• Morbidity 14%
• Receptor Blocking Agent 14%
• Pathophysiology 14%
• Autoimmune Disease 14%
• Mortality 14%
• Lung Fibrosis 14%
• Vascular Fibrosis 14%
• Finger Ulcer 14%

INIS

• hypertension 71%
• patients 57%
• diseases 42%
• endothelins 42%
• management 28%
• fibrosis 28%
• damage 28%
• evaluation 14%
• therapy 14%
• organs 14%
• production 14%
• reviews 14%
• mortality 14%
• receptors 14%
• morbidity 14%
• ulcers 14%